RxDoctor Payments Data

Frederick Askari, MD

Gastroenterology · Ann Arbor, MINPI 1689756108

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $370 of the $445 with a category attached, or 83.1%. AstraZeneca accounts for 83.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gastroenterology clinicians in MI, where the typical reported total is $1,620.

$445in general payments, 2019–2025

Across 2 payments — averaging $222.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$370
  • Orphalan Inc$75
$1,431,012in research payments, 2019–2025

Across 125 payments — averaging $11,448 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1M
  • Ultragenyx Pharmaceutical Inc.$387K
  • Intercept Pharmaceuticals, Inc.$17K

What the payments were for

  • Travel & lodging$37083%
  • Food & beverage$7517%

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$370
Orphalan Inc1$75

How this compares

$445 in reported general payments places this provider in the 30th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$45,886
Medicare patients
182
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CuvriorTrientine Tetrahydrochloride22$348,781
XifaxanRifaximin91$291,630
Ursodiol180$40,288
EliquisApixaban22$16,660
Envarsus XrTacrolimus30$13,421
VeltassaPatiromer Calcium Sorbitex16$13,089
Cyclosporine ModifiedCyclosporine, Modified69$12,113
Tacrolimus127$11,603
Trientine Hcl11$6,555
VascepaIcosapent Ethyl12$4,051
Azathioprine30$3,102
Mycophenolate Mofetil25$3,006
Lamivudine HbvLamivudine15$2,976
Entecavir34$2,285
Spironolactone68$1,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Orphalan IncCuvrior$75$348,78122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →